Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial
The Journal of Prevention of Alzheimer's Disease · 2024
DOI: 10.14283/jpad.2024.157 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Prevention of Alzheimer's Disease, 2024. Verfasst von M Ritchie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Marina Ritchie, MS, UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 3230 Biological Sciences III, University of Cal…. Hauptthemen laut MEDLINE: Alzheimer Disease, Motivation, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND: Many cognitively unimpaired older adults are interested in learning their Alzheimer's disease (AD) biomarker status, but little is known about motivations to undergo biomarker testing and result disclosure in the setting of preclinical AD trials. OBJECTIVES: Examine whether motivations to undergo AD biomarker testing and disclosure differ for individuals who have elevated amyloid compared to those with not elevated amyloid, and whether disclosure of amyloid results impacts participants' motivations. DESIGN, SETTING, PARTICIPANTS: We conducted post-hoc analyses using data from the EARLY study, a preclinical AD trial of the beta-secretase inhibitor atabecestat. As part of the screening process of the trial, participants underwent biomarker testing and disclosure. We analyzed data from n=2241 participants. MEASUREMENTS: We analyzed data from the Views and Perceptions of Amyloid Imaging (VPAI), a 9-item questionnaire assessing how strongly participants agreed with motivating factors for undergoing amyloid testing. The VPAI was administered at the first screening visit and again after amyloid disclosure. RESULTS: Prior to amyloid disclosure, a greater proportion of participants in the elevated amyloid group responded at the two highest levels of endorsement for the items, "to confirm the feeling that I might already be developing symptoms of AD dementia" (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marina Ritchie, MS, UC Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 3230 Biological Sciences III, University of California, Irvine, Email: mritchie@uci.edu.
Förderung
- NIA NIH HHS
Zitieren
APA
Ritchie, M., Raman, R., Ernstrom, K., Wang, S., Donohue, M. C., Aisen, P., Henley, D., Romano, G., Novak, G. P., Brashear, H. R., Sperling, R. A., & Grill, J. D. (2024). Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2024.157
Vancouver
Ritchie M, Raman R, Ernstrom K, Wang S, Donohue MC, Aisen P, et al. Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial. The Journal of Prevention of Alzheimer's Disease. 2024. doi:10.14283/jpad.2024.157
BibTeX
@article{Ritchie2024,
author = {Ritchie, M and Raman, R and Ernstrom, K and Wang, S and Donohue, M C and Aisen, P and Henley, D and Romano, G and Novak, G P and Brashear, H R and Sperling, R A and Grill, J D},
title = {Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial},
journal = {The Journal of Prevention of Alzheimer's Disease},
year = {2024},
doi = {10.14283/jpad.2024.157}
}
EUVIMED